featured-image

, /PRNewswire/ -- Abbott (NYSE: ) today announced financial results for the second quarter ended . "We achieved another quarter of strong growth in our underlying base business," said , chairman and chief executive officer, Abbott. "We have a lot of positive momentum heading into the second half of the year and are raising our full-year guidance.

" Refer to table titled "Non-GAAP Revenue Reconciliation" for a reconciliation of adjusted historical revenue to reported revenue. *Reflects the impact of discontinuing the ZonePerfect product line in the Nutrition business in and the acquisition of CSI on . Organic sales growth excludes the impact of the acquired business from January through .



Worldwide Nutrition sales increased 3.5 percent on a reported basis and 7.5 percent on an organic basis in the second quarter.

In Pediatric Nutrition, global sales increased 3.4 percent on a reported basis and 5.0 percent on an organic basis.

Sales in the U.S. reflect continued market share gains in the infant formula business.

In Adult Nutrition, global sales increased 3.7 percent on a reported basis and 9.9 percent on an organic basis, which was led by strong growth of Ensure , Abbott's market-leading complete and balanced nutrition brand.

As expected, Diagnostics sales growth in the second quarter was negatively impacted by year-over-year declines in COVID-19 testing-related sales . Worldwide COVID-19 testing sales were in the second quarter of 2024 compared to in the second quarter of the .

Back to Health Page